Recent Posts
- Secretome Therapeutics Appoints Dr. Marshelle Smith Warren as Chief Medical Officer
- Secretome Therapeutics Announces First Patient Dosed in Groundbreaking Phase 1 Study of STM-01 in Heart Failure with Preserved Ejection Fraction
- Secretome Therapeutics Granted FDA Fast Track Designation for STM-01, a Neonatal Cardiac Progenitor Cell Therapy for HFpEF
- Cellipont Bioservices and Secretome Therapeutics Partner for cGMP Manufacturing for Master Cell Bank for Lead Asset STM-01
- Secretome Therapeutics Closes $20.4 Million Financing Round to Advance Cardiomyopathy and Heart Failure Therapies